Cabazitaxel
- Generic Name
- Cabazitaxel
- Brand Names
- Jevtana, Cabazitaxel Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C45H57NO14
- CAS Number
- 183133-96-2
- Unique Ingredient Identifier
- 51F690397J
- Background
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrie...
- Indication
用于治疗转移性去势抵抗性前列腺癌患者。
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 675
- Registration Number
- NCT06691984
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Conditions
- Interventions
- Other: Genetic testingDrug: Valemetostat TosylateProcedure: Magnetic Resonance ImagingProcedure: Computed TomographyProcedure: Bone scanProcedure: FDG-Positron Emission TomographyProcedure: PSMA PET ScanProcedure: Biospecimen CollectionDrug: CarboplatinDrug: CabazitaxelDrug: Abiraterone AcetateDrug: EnzalutamideDrug: Lutetium Lu 177 Vipivotide Tetraxetan
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 474
- Registration Number
- NCT06632977
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
- Conditions
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 528
- Registration Number
- NCT06470243
- Locations
- 🇺🇸
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
🇺🇸Highlands Oncology Group - Rogers, Rogers, Arkansas, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 220
- Registration Number
- NCT06353386
- Locations
- 🇨🇦
Centre Hospitalier de l'Université de Montréal ( Site 0200), Montréal, Quebec, Canada
🇵🇱Uniwersyteckie Centrum Kliniczne ( Site 1405), Gdansk, Pomorskie, Poland
🇬🇧Addenbrooke's Hospital ( Site 1902), Cambridge, Cambridgeshire, United Kingdom
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06085729
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05818683
- Locations
- 🇺🇸
Washington University School Of Medicine, Saint Louis, Missouri, United States
🇺🇸Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05701007
- Locations
- 🇫🇮
Pfizer, Helsinki, Finland
Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Fundacion Oncosur
- Target Recruit Count
- 42
- Registration Number
- NCT05563558
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 44
- Registration Number
- NCT05340374
- Locations
- 🇦🇺
St Vincent's Hospital, Sydney, New South Wales, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Andrew J. Armstrong, MD
- Target Recruit Count
- 43
- Registration Number
- NCT04709276
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.